

Disclosure of received notification

Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification on 23 July 2015 from Danske Bank that the shareholding of Danske Bank has fallen below the disclosure threshold of 3%.

Based on the denominator of 31,667,794 (total number of voting rights) and the latest received notifications, the major shareholders of Fagron are:

	Number of shares	% of effective voting rights
Carmignac Gestion	2,463,267	7.78%
TIAA-CREF Asset Management LLC	1,635,681	5.17%
BNP Paribas Investment Partners SA	1,609,182	5.08%
Fidelity Management and Research (FMR LLC)	1,517,822	4.79%
Danske Bank	947,207	2.99%

The original notification forms are available on the website investors.fagron.com.

Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimizing and innovating pharmaceutical compounding. Fagron offers Fagron Compounding Services, Fagron Trademarks and Fagron Compounding Essentials to pharmacies, hospitals and patients in 32 countries worldwide. Pharmaceutical compounding is an essential part of pharmaceutical care that enables prescribers and pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D department consists of 45 researchers and more than 300 pharmacists who are working continually on developing new concepts, vehicles and formulations to treat an increasing number of patients with tailor-made compounded medication. The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra
Global Investor Relations Director
Tel. +31 88 33 11 213
marieke.palstra@fagron.com
investors.fagron.com

¹ This press release was sent out by Fagron NV and Fagron BV.

